Tijuana cancer clinics in the post-NAFTA era

Integrative Cancer Therapies

Volumn 4, Issue 1, 2005, Pages 65-86

  Moss, Ralph W ^a  

^a Cancer Communications Inc   (United States)

Author keywords

Amygdalin; Cancer; Clinics; Dendritic cells; Gerson; Herbs; Hoxsey; Laetrile; Mexico; NAFTA; Tijuana

Indexed keywords

AMYGDALIN; ASCORBIC ACID; CHLORIDE ION; COLEY TOXIN; CYTOTOXIC AGENT; DIMETHYL SULFOXIDE; INSULIN; LAETRILE; METHYLGLYOXAL; ONCOLYTIC VIRUS; PANCREAS ENZYME; RETINOL; SELENIUM; TOXIN; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ADOPTIVE IMMUNOTHERAPY; ALTERNATIVE MEDICINE; CANADA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CHELATION THERAPY; DENDRITIC CELL; DIET THERAPY; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; FORGERY; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH EDUCATION; HERBAL MEDICINE; HISTORY OF MEDICINE; HOMEOPATHY; HOSPITAL CHARGE; HUMAN; HYPERBARISM; LAW; LICENSING; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL FEE; MEDICAL LITERATURE; MEDICAL SOCIETY; MEXICO; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; OUTPATIENT CARE; OXYGEN THERAPY; POLITICS; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PUVA; REVIEW; ROSACEAE; SIDE EFFECT; T CELL LYMPHOMA; UNITED STATES; ARTICLE; COMMERCIAL PHENOMENA; ECONOMICS; HISTORY; INTERNATIONAL COOPERATION; LEGAL ASPECT; TRAVEL;

CANCER CARE FACILITIES; COMMERCE; COMPLEMENTARY THERAPIES; HISTORY, 20TH CENTURY; HUMANS; INTERNATIONAL COOPERATION; MEXICO; TRAVEL; UNITED STATES;

EID: 13844284209     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735404273918     Document Type: Review

References (74)

1. Crabtree P, Dibble S. Borderline medicine: Tijuana alternative clinics frustrate regulators. San Diego Union-Tribune, February 24, 2002. Available at: http://utawards.signonsandiego.com/borderline_medicine.html. Accessed September 17, 2004.
2. Harris R. Real Voice: Kefauver Drug Hearings, Englewood Cliffs, NJ: Regents/Prentice Hall; 1981.
3. About DSI. Division of Scientific Investigations, Food and Drug Administration, May 21, 2004. Available at: http://www.fda.gov/cder/Offices/DSI/ aboutUs.lum. Accessed October 23, 2004.
4. Vissing YM, Petersen JC. Taking Laetrile: conversion to medical deviance. CA Cancer J Clin. 1981;31:365-369.
5. Chowka PB, Mildred Nelson, RN: one year after her death, the Hoxsey therapy lives on. February 1, 2000. Available at: http://naturalhealthline.com/ newsletter/01feb00/nelson.htm. Accessed October 9, 2004.
6. Austin S, Dale EB, DeKadt S. Long term follow-up of cancer patients using Contreras, Hoxsey, and Gerson therapies. J Naturopath Med. 1994;5:74-76.
7. Richardson MA, Russell N, Sanders T, et al. Assessment of outcomes at alternative medicine cancer clinics: a feasibility study. J Altern Complement Med. 2001;7:19-32.
8. Young JH. Laetrile in historical perspective. In: Markle GE, Petersen JC, eds. Politics, Science and Cancer: The Laetrile Phenomenon. AAAS Selected Symposium 46. Boulder, Colo: Westview; 1980: 1-60.
9. Wilson B. The rise and fall of Laetrile. Revised February 17, 2004. Available at: http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/laetrile. html. Accessed October 13, 2004.
10. McGrady PM Jr. The American Cancer Society means well, but the Janker Clinic means better. Esquire. April 1976. Available at: http://www.canhelp.com/ articles/. Accessed October 22, 2004.
11. Kittler G. Laetrile: Nutritional Control for Cancer. Denver, Colo: Royal Publications; 1978.
12. Barren S. Manner metabolic therapy. Quackwatch Web site. July 1, 2001. Available at: http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/manner. html. Accessed October 20, 2004.
13. Manner H, DiSanti SJ, Michalsen TL. The Death of Cancer. Chicago, III: Advanced Century Publishing; 1979.
14. PDQ, National Cancer Institute. Laetrile/amygdalin: questions and answers. June 12, 2002. Available at: http://cis.nci.nih.gov/fact/9_3.htm. Accessed October 24, 2004.
15. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201-206.
16. Ward PS. History of the Gerson therapy. Contract report prepared for the US Office of Technology Assessment. Washington, DC: Government Printing Office; 1988. Available at: http://gerson-research.org/docs/WardPS-1988-1/. Accessed October 22, 2004.
17. Hess D. Evaluating Alternative Cancer Treatments. New Brunswick, NJ: Rutgers University Press; 1999.
18. Straus H. Max Gerson: Healing the Hopeless. Kingston, Ontario, Canada: Quarry Press; 2002.
19. Charles, Prince of Wales, President, Foundation for Integrated Health. Presented at: Complementary Therapies and Cancer Care: A Research Symposium; The Royal College of Obstetricians and Gynaecologists; Sussex Place, London; June 24, 2004. Available at: http://www.princeofwales.gov.uk/speeches/ health_24062004.html. Accessed October 20, 2004.
20. Chowka P. Action against two Tijuana cancer clinics casts doubt on the future of CAM south of the border. Natural HealthLine. March 1, 2001. Available at: http://naturalhealthline.com/newsletter/1mar01/tijuana.htm. Accessed September 17, 2004.
21. BioPulse International, Inc. (BIOP) announces Dr. Reid Jilek promoted to chairman of the board and CEO. Available at: http://www.biospace.com/news_story. cfm?StoryID= 4176104&full=1. Accessed October 22, 2004.
22. Smallen D. Bureau of Transportation Statistics (BTS). July transportation services index (TSI): combined index and passenger index at new highs. Available at: http://www.bts.gov/press_releases/2004/bts027_04/html/bts027_04. html. Accessed October 21, 2004.
23. Crabtree P, Dibble S. Borderline medicine: Tijuana alternative clinics frustrate regulators. San Diego Union-Tribune. February 24, 2002. Available at: http://utawards.signonsandiego.com/borderline_medicine.html. Accessed September 17, 2004.
24. Nationmaster.com. Map & graph: government; corruption 2003 (top 100 countries). Available at http://www.nationmaster. com/graph-T/gov_cor_200. Accessed October 21, 2004.
25. Lerner M. A trip to the Tijuana cancer clinics. Commonwealth Newsletter. May 15, 2001. Available at: http://www.commonweal.org/old-site/ bd_friends_5_15_2001.html. Accessed November 4, 2004.
26. Federal Trade Commission. FTC and FDA announce the adoption of an international agreement to combat health fraud. December 10, 1998. Available at: http://www.ftc.gov/opa/1998/12/health.htm. Accessed October 22, 2004.
27. Ciotti P. Faith, hope and fraud. Los Angeles Times. December 15, 1991. Available at: http://www.karlloren.com/Jimmy_Keller/page9.htm. Accessed October 21, 2004.
28. Landers SJ. Cancer center called sham, closed down. AMNews.com. March 10, 2003. Available at: http://www.ama-assn.org/amednews/2003/03/10/hlsa0310.htm. Accessed October 22, 2004.
29. Federal Trade Commission. FTC and FDA announce the adoption of an international agreement to combat health fraud. December 10, 1998. Available at: http://www.ftc.gov/opa/1998/12/health.htm. Accessed October 22, 2004.
30. American Cancer Society. Questionable cancer practices in Tijuana and other Mexican border clinics, 1991. CA Cancer J Clin. 1991;41:310-319.
31. Crabtree P, Dibble S. No insurance against fraud: false claims often flourish alongside unproven therapies. San Diego Union-Tribune. February 24, 2002. Available at: http://www.signonsandiego.com/news/reports/tjclinics/ 20020224-9999-insurance.html. Accessed October 20, 2004.
32. Canon S. Medical Mecca? Tijuana clinics draw plain people. Kansas City Star. October 22, 1996. Available at: http://www.kcstar.com/plain/stories/ amish22.htm. Accessed October 13, 2004.
33. Moss R. Herbs Against Cancer. New York, NY: Equinox; 1998.
34. McNeil C, Collinson F, Smith K, et al. Delay in conventional breast cancer treatment associated with alternative therapy usage [abstract]. J Clin Oncol. 2004;22 (14S):593. Abstract 593.
35. Moss RW. 2004 ASCO meeting, part one. Cancer Decisions Newsletter. June 13, 2004. Available at: http://www.cancerdecisions.com/061304_page.html. Accessed October 23, 2004.
36. Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apheresis Sci. 2002;26:181-90.
37. Hoption Cann SA, van Netten JP, van Netten C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002;58:115-119.
38. Contreras F. Biographical statement. Cancer Control Society speakers, 31st Annual Cancer Convention, 2003. Available at: http://www. cancercontrolsociety.com/bio2003/contreras.html. Accessed October 23, 2004.
39. Rodriguez R. Biographical statement. Cancer Control Society speakers, 31st Annual Cancer Convention, 2003. Available at: http://www. cancercontrolsociety.com/bio2003/rodriguez.html. Accessed October 23, 2004.
40. Clemenceau Valdivia J-R. First SMEO Mexican patient seminar Mexican: oncologists reaching out to patients. ESMO Newsletter. January-March 2004. Available at: www.esmo.org/news/pdf/NL0104.pdf. Accessed October 20, 2004.
41. Staffing firm reports physicians' salaries growing. Modern Healthcare. June 24, 2002. Available at: http://modernhealthcare.com/login.cms. Accessed October 22, 2004.
42. Pousson P. What's it like to go to a Mexican hospital for cancer treatment? Available at: http://www.alternative-cancer.net/index.html. Accessed October 21, 2004.
43. Lowell JA. Mexican cancer clinics. In: Barrett S, Cassileth BR, eds. Dubious Cancer Treatment. Tampa, Fla: American Cancer Society, Florida Division; 1991.
44. Smith L. Quacky Mexican clinics. CancerGuide Web site, 2001. Available at: http://www.cancerguide.org/lsmith_hulda.html. Accessed October 19, 2004.
45. Leaf C. Why we're losing the war on cancer-and how to win it. Fortune. March 9, 2004. Available at: http://www.fortune.com/fortune/articles/0,15114, 598425,00.html. Accessed October 25, 2004.
46. von Eschenbach AC. A vision for the national cancer program in the United States. Nat Rev Cancer. 2004;4:820-828.
47. Cassileth BR. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center. Semin Oncol. 2002;29:585-588.
48. Yates J, Morrow G, Mustian M, et al. Are cancer patients utilizing complementary therapies? A URCC CCOP study. J Clin Oncol. 2004;22:8157..
49. Soto OR, Dibble S. Operators of Tijuana clinic arrested on fraud charges. San Diego Union-Tnbune. May 20, 2004. Available at: http://www.signonsandiego. com/news/business/20040520-9999-1b20cancer.html. Accessed October 24, 2004.
50. World Health Organization. Global cancer rates could increase by 50% to 15 million by 2020. Available at: http://www.who.int/mediacentre/news/releases/ 2003/pr27/en/. Accessed October 28, 2004.
51. Epstein SS. Legislative proposals for reversing the cancer epidemic and controlling run-away industrial technologies. Int J Health Serv. 2000;30:353-371.
52. Mumcuoglu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol. 2001;2:219-227.
53. Syrigos KN, Rowlinson-Busza G, Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer. 1998;78:712-719.
54. Kwon HY, Hong SP, Hahn DH, Kim JH. Apoptosis induction of persicae semen extract in human promyelocytic leukemia (HL-60) cells. Arch Pharm Res. 2003;26:157-161.
55. Fiikuda T, Ito H, Mukainaka T, et al. Anti-tumor promoting effect of glycosides from Prunus persica seeds. Biol Pharm Bull. 2003;26:271-273.
56. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
57. Payer L. Medicine and Culture: Revised Edition. New York, NY: Owl Books; 1996.
58. Shibata M, Suzuki M, Abe H, et al. Immunomodulatory effects and survival benefit of low dose cisplatin combined with UFT and PSK [abstract]. Proc Am Soc Clin Oncol. 2003;22:357. Abstract 1433.
59. American Cancer Society. Coriolus versicolor. Available at: www.cancer.org/docroot/ETO/content/ETO_5_3X_ Coriolous_Versicolor.asp?sitearea= ETO. Accessed October 19, 2004.
60. Beuth J, ed. Grundlagen der Komplementär-Onkologie: Theorie und Praxis. Stuttgart, Germany: Hippocrates Verlag; 2002.
61. Alliance Pharmaceuticals. Phases of product development, 2004. Available at: http://www.allp.com/drug_dev.htm.
62. Pelton R, Overholser L. Alternatives in Cancer Therapy: The Complete Guide to Non-traditional Treatments. New York, NY: Fireside; 1994.
63. McLearn D. Federal-state investigation of illegal drugs. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00495.html. Accessed October 22, 2004.
64. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342-4346.
65. Shaving chemotherapy: killing patients with kindness. Med World News. 1986;27:24-25.
66. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
67. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
68. Memorial Sloan-Kettering Cancer Center. Integrative medicine. Available at: http://www.mskcc.org/mskcc/html/1979.cfm. Accessed December 9, 2004.
69. White JD. The National Cancer Institute's perspective and agenda for promoting awareness and research on alternative therapies for cancer. J Altern Complement Med. 2002;8:545-550.
70. Cancer Advisory Panel for Complementary and Alternative Medicine, National Institutes of Health. Minutes of the third meeting, September 18, 2000. Available at: http://nccam.nih. gov/about/advisory/capcam/minutes/2000sept.htm. Accessed November 5, 2004.
71. Friedman T. The Lexus and the Olive Tree. New York, NY: Farrar, Straus & Giroux; 2000.
72. Fink J. Third Opinion: An International Directory to Alternative Therapy Centers for the Treatment and Prevention of Cancer & Other Degenerative Diseases. 4th ed. Garden City Park, NY: Square One Publishers; 2004.
73. Rodriguez EC, Pulido JEC, Price AM. Phase III study of inoperable lung cancer: antitumoral effects of amygdalin in patients with inoperable lung cancer. Available at: www. worldwithoutcancer.org.uk/analysis13.html. Accessed November 23, 2004.
74. Hildenbrand GL, Hildenbrand LC, Bradford K, Cavin SW. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Ther Health Med. 1995;1:29-37.